Opportunities and hurdles in the treatment of BRCA1-related breast cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Oncogene

• Publication date

  2014-07-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2013.329PMID 23955079
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase

  2013cited by this paper
• BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation

  2013cited by this paper
• Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

  2012cited by this paper
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  2012cited by this paper
• BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair.

  2012cited by this paper
• Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro

  2012cited by this paper
• Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

  2012cited by this paper
• Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.

  2012cited by this paper
• The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

  2012cited by this paper
• The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

  2012cited by this paper
• Links between genome integrity and BRCA1 tumor suppression.

  2012cited by this paper
• BRCA1 tumor suppressor network: focusing on its tail

  2012cited by this paper
• Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

  2012cited by this paper
• Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models

  2012cited by this paper
• Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.

  2012cited by this paper
• Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition.

  2012cited by this paper
• A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

  2012cited by this paper
• BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

  2011cited by this paper
• BRCA1 tumor suppression occurs via heterochromatin mediated silencing

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• BRCA1 is required for postreplication repair after UV-induced DNA damage.

  2011cited by this paper
• Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• DNA interstrand crosslink repair and cancer

  2011cited by this paper
• Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

  2011cited by this paper
• Targeting the Akt/mTOR pathway in Brca1-deficient cancers

  2011cited by this paper
• Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition

  2011cited by this paper
• Inherited Mutations in Breast Cancer Genes—Risk and Response

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

  2011cited by this paper
• Clinical Management of Hereditary Breast Cancer Syndromes

  2011cited by this paper
• BRCA1 Tumor Suppression Depends on BRCT Phosphoprotein Binding, But Not Its E3 Ligase Activity

  2011cited by this paper
• BRCA1 and BRCA2: different roles in a common pathway of genome protection

  2011cited by this paper
• Gene expression profiling in breast cancer: classification, prognostication, and prediction.

  2011cited by this paper
• Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

  2011cited by this paper
• The BRCA1 ubiquitin ligase and homologous recombination repair

  2011cited by this paper
• Unraveling the mechanism of BRCA2 in homologous recombination

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• PARP inhibitors stumble in breast cancer

  2011cited by this paper
• Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

  2010cited by this paper
• Purified human BRCA2 stimulates RAD51-mediated recombination

  2010cited by this paper
• Human BRCA2 protein promotes RAD51 filament formation on RPA-covered ssDNA

  2010cited by this paper
• Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo

  2010cited by this paper
• The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA

  2010cited by this paper
• An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.

  2010cited by this paper
• BRCA1 and its toolbox for the maintenance of genome integrity

  2010cited by this paper
• 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

  2010cited by this paper
• Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

  2010cited by this paper
• Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.

  2010cited by this paper
• BRCA1 expression in triple negative sporadic breast cancers.

  2010cited by this paper
• Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

  2010cited by this paper
• BRCA1 16 years later: DNA damage‐induced BRCA1 shuttling

  2010cited by this paper
• Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis

  2010cited by this paper
• 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors

  2009cited by this paper
• High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

  2009cited by this paper
• Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

  2009cited by this paper
• Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.

  2009cited by this paper
• PALB2 links BRCA1 and BRCA2 in the DNA-damage response.

  2009cited by this paper
• PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2

  2009cited by this paper
• PALB2 is an integral component of the BRCA complex required for homologous recombination repair

  2009cited by this paper
• Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

  2009cited by this paper
• Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

  2009cited by this paper
• Prognosis of BRCA-associated breast cancer: a summary of evidence

  2009cited by this paper
• Detection of mutations in EGFR in circulating lung-cancer cells.

  2008cited by this paper
• Basal-like breast cancer: a critical review.

  2008cited by this paper
• Negative Regulation of AKT Activation by BRCA1.

  2008cited by this paper
• The potential role and application of PARP inhibitors in cancer treatment.

  2008cited by this paper
• Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

  2008cited by this paper
• Resistance to therapy caused by intragenic deletion in BRCA2

  2008cited by this paper
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

  2008cited by this paper
• The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression

  2008cited by this paper
• Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.

  2008cited by this paper
• Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

  2008cited by this paper
• Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6‘split apart’ probes

  2008cited by this paper
• Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

  2008cited by this paper
• Cell Cycle-dependent Complex Formation of BRCA1·CtIP·MRN Is Important for DNA Double-strand Break Repair*

  2008cited by this paper
• Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.

  2008cited by this paper
• Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

  2008cited by this paper
• Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

  2008cited by this paper
• Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair

  2008cited by this paper
• Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells.

  2008cited by this paper
• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

  2008cited by this paper
• E2–BRCA1 RING interactions dictate synthesis of mono- or specific polyubiquitin chain linkages

  2007cited by this paper
• Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response

  2007cited by this paper
• Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

  2007cited by this paper
• Molecular mechanisms of resistance and toxicity associated with platinating agents.

  2007cited by this paper
• Proteasome function is required for DNA damage response and fanconi anemia pathway activation.

  2007cited by this paper
• Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.

  2007cited by this paper
• BRCA1 dysfunction in sporadic basal-like breast cancer

  2007cited by this paper

• Systematic investigation of BRCA1-A, -B, and -C complexes and their functions in DNA damage response and DNA repair

  2024cites this paper
• Identification of Novel Functional Single Nucleotide Polymorphisms in the BRCA1 Gene of Breast Cancer Patients

  2024cites this paper
• BMI‐1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes

  2022cites this paper
• BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy.

  2022cites this paper
• BBIT20 inhibits homologous DNA repair with disruption of the BRCA1–BARD1 interaction in breast and ovarian cancer

  2021cites this paper
• Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target

  2021influential citation
• The Present and Future of the Treatment of Hereditary Breast Cancer

  2021cites this paper
• PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors

  2021cites this paper
• A new microfluidic concept for successful in vitro culture of mouse embryos

  2020cites this paper
• BRCA1/P53: Two strengths in cancer chemoprevention.

  2020cites this paper
• A Novel Mutation-BRCA1 Associated Hereditary Haplotype of Intragenic Markers of BRCA1 Gene in a Family with History of Breast Cancer

  2019cites this paper
• Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

  2019cites this paper
• Expression of miR-146a-5p in breast cancer and its role in proliferation of breast cancer cells

  2018cites this paper
• Chapter 7 The BRCA 1 and BRCA 2 Breast and Ovarian Cancer Susceptibility Genes — Implications for DNA Damage Response , DNA Repair and Cancer Therapy

  2018cites this paper
• Detection of a novel mutations in Exon 11 of BRCA1 gene in the patients with hereditary breast cancer

  2018cites this paper
• Breast cancer intrinsic subtypes: a critical conception in bioinformatics

  2017cites this paper
• BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells

  2017cites this paper
• Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms

  2017cites this paper
• The BRCA 1 and BRCA 2 Breast and Ovarian Cancer Susceptibility Genes — Implications for DNA Damage Response , DNA Repair and Cancer Therapy

  2017cites this paper
• PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells

  2017cites this paper
• Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.

  2016cites this paper
• BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells

  2016cites this paper
• Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas

  2016cites this paper
• Emerging therapeutic targets in metastatic progression: A focus on breast cancer.

  2016cites this paper
• Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.

  2016cites this paper
• Time to Diagnosis of Second Primary Cancers among Patients with Breast Cancer

  2016cites this paper
• The identification of novel strategies for the prevention and treatment of breast cancer in BRCA1-mutation carriers

  2016cites this paper
• High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.

  2016cites this paper
• MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression

  2016cites this paper
• Deregulated microRNAs in breast cancer and their potential role as diagnostic and prognostic biomarkers

  2015cites this paper
• The BRCA1 and BRCA2 Breast and Ovarian Cancer Susceptibility Genes — Implications for DNA Damage Response, DNA Repair and Cancer Therapy

  2015cites this paper
• Analysis of haploinsufficiency in women carrying germline mutations in the BRCA1 gene: Different mutations, different phenotypes ?

  2015influential citation
• PARP Inhibitor Resistance - What Is Beyond BRCA1 or BRCA2 Restoration?

  2015cites this paper
• Heteroleptic Pd(II) dithiocarbamates: synthesis, characterization, packing and in vitro anticancer activity against HeLa cell line

  2015cites this paper
• Linear polyethyleneimine-doxorubicin conjugate for pH-responsive synchronous delivery of drug and microRNA-34a

  2015cites this paper
• A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy

  2014cites this paper
• Mutational Landscape of the Essential Autophagy Gene BECN1 in Human Cancers

  2014cites this paper
• Cooperation between BRCA 1 and vitamin D is critical for histone acetylation of the p 21 waf 1 promoter and for growth inhibition of breast cancer cells and cancer stem-like cells

  2014cites this paper
• A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy

  2014cites this paper
• Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and for growth inhibition of breast cancer cells and cancer stem-like cells

  2014cites this paper
• Sensitive and selective DNA probe based on “turn-on” photoluminescence of C-dots@RGO

  2014cites this paper
• BRCA1 as target for breast cancer prevention and therapy.

  2014cites this paper